Posted by Michael Wonder on 08 Jul 2025
Lexeo Therapeutics announces FDA breakthrough therapy designation for LX2006 in Friedreich ataxia
7 July 2025 - Breakthrough therapy designation based on interim clinical data from Phase I/II trials showing clinically meaningful improvements in cardiac biomarkers and functional measures.
Lexeo Therapeutics today announced that the US FDA has granted breakthrough therapy designation to LX2006 based on clinical evidence generated on both cardiac and neurologic measures of Friedreich ataxia.
